MedTrace Logo

A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2

NCT05331885 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-24

No results posted yet for this study

Summary

Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients

Conditions

  • Ventilator Associated Pneumonia
  • Staphylococcus Aureus

Interventions

BIOLOGICAL

Suvratoxumab

Monoclonal antibody

DRUG

Placebo

Placebo contains only excipients

Sponsors & Collaborators

  • Aridis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Francois, MD · Centre Hospitalier Universitaire (CHU) de Limoges

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-02
Primary Completion
2024-07-08
Completion
2024-07-08
FDA Drug
Yes

Countries

  • Belgium
  • France
  • Greece
  • Israel
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05331885 on ClinicalTrials.gov